Melatonin: an essential factor for the treatment and recovery from leukemia and cancer
Melatonin: an essential factor for the treatment and recovery from leukemia and cancer(full PDF)
In addition to its endocrine effects, othen non-endocrine functions have been attributed to its pineal gland, such as those displayed on the CNS (1).
And yet habenular nuclei stimulation causes an increase in blood platelet count (2), in the same manner as injected Melatonin, particularly in the case of splenechtomized and/or eipnephrectomized rats.
According to our belief, the platelets, and Melatonin too, play an essential role in leukemia etiopathogenesis; we have therefore assayed the effects of Melatonin treatment on leukemia and cancer patients for seven years (since 1974), with the following results:
- It is pratically impossible to eradicate leukemia or cancer without Melatonin treatment;
- Melatonin is a necessary, though by itself alone, not sufficient, remedy for leukemia and cancer cure;
- A supporting action is often simultaneously required, that rests upon a parallel use of ACTH, of anti-free-radical drugs, ADH, SRIF, PIF, mineralcorticoids;
- Melatonin may be administered by mouth, as well as parenteral route, without any dangerous instant or late effect, even though the administering is protracted for months or years;
- Some leukemia patients have arbitrarly discontinued the Melatonin therapy, without any trouble or relapse. That supports the convinction that leukemia can be truly definetively healed;
- The treatment does non generally entail, or only rarely, anu hospitalization, apart from a periodic blood analysis;
- Myeloid, acute or chronic, luekemia has to be cured with significantly lower dosages of Melatonin;
- Good or excellent results have been reached in epithelial or connective tissue tumors, where a steady yearslong equilibrium may be reached, which allows a normal, or almost usual existence.
The mechanism Melatonin works with, is a manifold one. The main topics are perhaps the inhibition of GH and prolactin secretion (3), and the impairment of mitosis (4).
See also:
- Official Web Site: The Di Bella Method;
- Melatonin use in cancer patients have started in 1974, when melatonin prepared according to Prof. Di Bella’s formulation [...]. For 11 days was administered to the patient, admitted to the general medical ward at the Maggiore-Pizzardi Hospital in Bologna, very slowly (over approx. 8 hours) and intravenously administered 1000 mg of melatonin for 11 days. During the course of each day, the patient was intravenously administered 4 saline drips of 500 ml, each containing ten 25 mg bottles of freeze-dried melatonin, lasting 2 hours, totaling 1000 mg per day. No other drug of any kind was administered in order to ascertain the effect of the MLT without interference [...]. From Melatonin with adenosine solubilized in water and stabilized with glycine for oncological treatment - technical preparation, effectivity and clinical findings (Di Bella's Foundation);
- About Melatonin - In vitro, review and in vivo publications;
- Publication: Melatonin anticancer effects: Review (from Di Bella's Foundation);
- Publication: Key aspects of melatonin physiology: 30 years of research (from Di Bella's Foundation);
Melatonin: an essential factor for the treatment and recovery from leukemia and cancer
References
[1] F. Antón-Tay, J.L. Díaz, A. Fernández-Guardiola - On the effect of melatonin upon human brain. Its possible therapeutic implications. Life Sci I. 1971 Aug 1;10(15):841-50. doi: 10.1016/0024-3205(71)90155-x:
[2] L Di Bella, M T Rossi, G Scalera - Perspectives in pineal functions. Prog Brain Res. 1979:52:475-8. doi: 10.1016/s0079-6123(08)62954-4;
[3] J L Kostyo, O Isaksson - Growth hormone and the regulation of somatic growth. Int Rev Physiol. 1977:13:255-74;
[4] S Banerjee, L Margulis - Mitotic arrest by melatonin. Exp Cell Res. 1973 Apr;78(2):314-8. doi: 10.1016/0014-4827(73)90074-8.